Role of chemotherapy in the very elderly patients with metastatic pancreatic cancer - A Veterans Affairs Cancer Registry analysis

Journal of Geriatric Oncology

Volumn 2, Issue 3, 2011, Pages 209-214

  Aldoss, Ibrahim T ^a,c   Tashi, Tsewang ^a,c,d   Gonsalves, Wilson ^a,c,d   Kalaiah, Ranin K ^a,c,d   Fang, Xiang ^e   Silberstein, Peter ^a,c,d   Ganti, Apar K ^b,c,d   Subbiah, Shanmuga ^a,c,d  

^a CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c Division of Internal Medicine   (United States)

^d VA Nebraska Western Iowa Health Care System   (United States)

^e CREIGHTON UNIVERSITY   (United States)

Author keywords

Chemotherapy; Elderly patients; Pancreatic cancer

Indexed keywords

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER REGISTRY; CANCER SURVIVAL; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS CANCER; SMOKING; SURVIVAL TIME;

EID: 79958728624     PISSN: 18794068     EISSN: 18794076     Source Type: Journal    
DOI: 10.1016/j.jgo.2011.02.003     Document Type: Article

References (35)

1. Sener S.F., Fremgen A., Menck H.R., Winchester D.P. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 1999, 189:1-7.
2. Niederhuber J.E., Brennan M.F., Menck H.R. The National Cancer Database report on pancreatic, cancer. Cancer 1995, 76:1671-1676.
3. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 2009, 59(4):225-249.
4. Nieto J., Grossbard M.L., Kozuch P. Metastatic pancreatic cancer 2008: is the glass less empty?. Oncologist 2008, 13:562-576.
5. Stathis A., Moore M.J. Advanced pancreatic cancinoma: current treatment and future challenges. J Nat Rev Clin Oncol 2010, 7:163-172.
6. Burris H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15:2403-2413.
7. Moore M.J., Goldstein D., Hamm J., Figer A., Hecht J.R., Gallinger S., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007, 25(15):1960-1966.
8. Colucci G., Giuliani F., Gebbia V., Biglietto M., Rabitti P., Uomo G., et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 2002, 94(4):902-910.
9. Rocha Lima C.M., Green M.R., Rotche R., Miller W.H., Jeffrey G.M., Cisar L.A., et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004, 22(18):3776-3783.
10. Louvet C., Labianca R., Hammel P., Lledo G., Zampino M.G., Andre T., et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005, 23(15):3509-3516.
11. Oettle H., Richards D., Ramanathan R.K., van Laethem J.L., Peeters M., Fuchs M., et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 2005, 16(10):1639-1645.
12. Abou-Alfa G.K., Letourneau R., Harker G., Modiano M., Hurwitz H., Tchekmedyian N.S., et al. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol 2006, 24(27):4441-4447.
13. Heinemann V., Quietzsch D., Gieseler F., Gonnermann M., Schönekäs H., Rost A., et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006, 24(24):3946-3952.
14. Stathopoulos G.P., Syrigos K., Aravantinos G., Polyzos A., Papakotoulas P., Fountzilas G., et al. A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer 2006, 95(5):587-592.
15. Cunningham D., Chau I., Stocken D.D., Valle J.W., Smith D., Steward W., et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009, 27(33):5513-5518.
16. Colucci G., Labianca R., Di Costanzo F., Gebbia V., Cartenì G., Massidda B., et al. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol 2010, 28:1645-1651.
17. Hutchins L.F., Unger J.M., Crowley J.J., Coltman C.A., Albain K.S. Underrepresentation of patients 65years of age or older in cancer-treatment trials. N Engl J Med 1999, 341:2061-2067.
18. Folprecht G., Cunningham D., Ross P., Glimelius B., Di Costanzo F., Wils J., et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol 2004, 15:1330-1338.
19. Greil R. Prognosis and management strategies of lymphatic neoplasias in the elderly. I. Aggressive non-Hodgkin's lymphomas. Oncology 1998, 55:189-217.
20. Siu L.L., Shepherd F.A., Murray N., Feld R., Pater J., Zee B., et al. Influence of age on the treatment of limited-stage small-cell lung cancer. J Clin Oncol 1996, 14:821-828.
21. Langer C.J., Manola J., Bernardo P., Kugler J.W., Bonomi P., Cella D., et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002, 94:173-181.
22. Deyo R.A., Cherkin D.C., Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992, 45:613-619.
23. D'Hoore W., Sicotte C., Tilquin C. Risk adjustment in outcome assessment: the Charlson comorbidity index. Meth Inf Med 1993, 32:382-387.
24. Rochon P.A., Katz J.N., Morrow L.A., McGlinchey-Berroth R., Ahlquist M.M., Sarkarati M., et al. Comorbid illness is associated with survival and length of hospital stay in patients with chronic disability. Med Care 1996, 34:1093-1101.
25. Charlson M.E., Pompei P., Ales K.L., MacKenzie A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987, 40:373-383.
26. Avery E.J., Kessinger A., Ganti A.K. Therapeutic options for elderly patients with advanced non-small cell lung cancer. Cancer Treat Rev 2009, 35(4):340-344.
27. Extermann M., Overcash J., Lyman G.H., Parr J., Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998, 16:1582-1587.
28. Frasci G., Lorusso V., Panza N., Comella P., Nicolella G., Bianco A., et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2000, 18:2529-2536.
29. Freyer G., Geay J.F., Touzet S., Provencal J., Weber B., Jacquin J.P., et al. Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. Ann Oncol 2005, 16:1795-1800.
30. Sundararajan V., Mitra N., Jacobson J.S., Grann V.R., Heitjan D.F., Neugut A.I. Survival associated with5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med 2002, 136:349-357.
31. Folprecht G., Rougier P., Saltz L., et al. Irinotecan in first line therapy of elderly and non-elderly patients with metastatic colorectal cancer: metaanalysis of three trials investigating 5-FU and irinotecan. Proc Am Soc Clin Oncol 2006, 24(18). (abstr 3578).
32. Ricci S., Antonuzzo A., Galli L., Tibaldi C., Bertuccelli M., Lopes Pegna A., et al. Gemcitabine monotherapy in elderly patients with advanced non-small-cell lung cancer: a multicenter phase II study. Lung Cancer 2000, 27:75-80.
33. Tonato M., Mosconi A.M., Martin C. Safety profile of gemcitabine. Anticancer Drugs 1995, 6(6):27-32.
34. Martin C., Ardizzoni A., Rosso R. Gemcitabine: safety profile and efficacy in non-small cell lung cancer unaffected by age. Aging 1997, 9:297-303.
35. Census Bureau U.S. 65+ in the United States: 2005 http://www.census.gov/prod/2006pubs/p23-209.pdf.